anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Levels of VEGF are elevated in eyes wth Diabetic Macular Edema and the expression of VEGF was found to be elevated temporarily following the photocoagulation of human Retinal Pigment Epithelial (RPE) cells. Ranibizumab (Lucentis TM, Genentech) is an anti-VEGF antibody shown to have properties to prevent macular edema. We hypothesize that VEGF inhibition can effectively treat PRP-induced macular edema, thereby minimizing post-PRP vision loss.

Subjects who meet eligibility criteria will receive 0.5mg ranibizumab administered 7-14 days post-PRP. Additional intravitreal injections of 0.5 mg of ranibizumab at Day 30 and/or Day 60 may be also be administered. All subjects will be followed for 90 days for safety and efficacy assessments. There is no placebo or sham arm of this trial.
Patients will undergo a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor. Hematopoietic stem cell donors for this trial will include individuals who are 10/10 HLA matched or one antigen or allele mismatched at the HLA-A, B, C, DRB1 or DQB1 locus, as defined by high resolution methods .Donors who are 8/10 HLA matched with an antigen or allele mismatched at HLA-DQB1 and at one other locus will also be eligible for the trial. The administration of WT1-specific cytotoxic T cells (WT1 CTLs) post transplantation is integrated to induce complete remissions in patients with residual disease and to decrease the rate of relapse following the allogeneic transplant.
All patients who applied to the orthopedics and traumatology department between July 2017 and June 2018 for a medical board examination were evaluated by physical and radiological examination. Healthy individuals who applied for the same examination and met the inclusion criteria were determined as the control group by random sampling method. All participants were evaluated by a senior psychiatrist. Before the interview, all subjects fully informed about the purpose and scope of the study. After their permission was obtained the control group completed a socio-demographic data form consisting of questions about detailed personal and medical history and, the participants were asked to fill in the TCI.
A formulation for pain management is described for use by individuals experiencing pain. The formulation comprises a plurality of cannabinoids in optimized amounts to manage pain.  One or more excipient, diluent or carrier is included in the formulation.  The types of pain to be managed with the formulation include but are not limited to the treatment of pain due to cancer, injury, accident, surgery, neuropathic pain or tissue damage. The primary cannabinoids are present in the formulation in amounts according to a ratio of THC: CB C:CBD ranging from 5:5:5 to 5:1:5. Methods of use of the formulation, doses and dosage forms are described which may have 5:5:5 mg or more of CBD:CBC:THC are described.
The present invention relates to a health-care food for preventing and curing pharyngolaryngitis, and a preparation method thereof. The health-care food is mainly composed of honeysuckle flower, mongolian dandelion herb, ophiopogon root, boat-fruited sterculia and peppermint oil; the health-care food can be prepared into various oral-administration preparations in a production method of a common technique, such as tablets, pellets, dripping pills, granules, oral liquid, vapor agents, spraying agents, powder agents, ointment, medicinal powder, etc., and can be made into beverages, candys and tea bags. The preparation method of the tablets comprises the processes of ointment extraction and tablet production. The health-care food is prepared by sieving medicine-food dual-purpose Chinese herbal medicines having the functions of resisting bacteria, resisting viruses, clearing heat and toxin, relieving sore throats, restoring voice, dispersing lung qi, dissipating phlegm, moistening the lung, nourishing yin and reducing fever and having no toxic or side effect by long-time administration, and thus, the health-care food fully has the curative effect on congestion, reddish swelling, burning and pain of throats, hoarse voice, dry itchy throats, and cough resulting from acute and chronic pharyngolaryngitis, and has health-care functions of clearing the lung, relieving sore throats, eliminating mouth-cavity abnormal smell, etc. for smoking people. The health-care food adopts xylitol as a flavoring agent and does not contain sugar, and thus, the application range is enlarged.
Milrinone drawn from vials should be diluted prior to maintenance dose administration. The diluents that may be used are 0.45% Sodium Chloride Injection, USP, 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP. The table below shows the volume of diluent in milliliters (mL) that must be used to achieve 200 mcg/mL concentration for infusion, and the resultant total volumes.  


The infusion rate should be adjusted according to hemodynamic and clinical response. Patients should be closely monitored. In controlled clinical studies, most patients showed an improvement in hemodynamic status as evidenced by increases in cardiac output and reductions in pulmonary capillary wedge pressure.

Note: See “Dosage Adjustment in Renally Impaired Patients” Dosage may be titrated to the maximum hemodynamic effect and should not exceed 1.13 mg/kg/day. Duration of therapy should depend upon patient responsiveness.

The maintenance dose in mL/hr by patient body weight (kg) may be determined by reference to the following table.

When administering milrinone lactate by continuous infusion, it is advisable to use a calibrated electronic infusion device.

Intravenous drug products should be inspected visually and should not be used if particulate matter or discoloration is present.
Drug: Nicorandil (Chugai Pharmaceutical Co, Japan). The first dose is given 8h before selective percutaneous coronary intervention, 10mg, oral. After the percutaneous coronary intervention, nicorandil is given for 30 days, 5mg each time, 3 times daily oral.
3-4 grade radiation mucositis account for 34%-56% in all head and neck patients treated by radiotherapy and \>50% in patients treated by radiotherapy concurrent with chemotherapy. 3-4 grade radiation mucositis have obvious symptoms, presenting with fusion ulcers, ulcers bleeding or obvious pain need analgesic drugs. At this time, the patients can not eat or can only intake fluid diet, which led to weight loss, malnutrition, quality of life declined and a series of problems.

Kanglaite has anti-tumor effect and reduce treatment toxicity of tumor. Kanglaite can reduce radiotherapy mucositis of nasopharyngeal cancer had been found initially in Chinese. Kanglaite on the prevention and treatment of radiation mucositis of the head and neck malignant tumor is still lack of strong clinical trial evidence. This is a phase II, single center, one arm study with subject to evaluation the acute radiation mucositis, nutritional status, and quality of life on the course of radiotherapy of head and neck malignant tumors.

Kanglaite 200ml is injected intravenous from the first day to the last day of radiotherapy. Chemotherapy with cisplatin or nedaplatin (both 80-100mg/m2, 21 day per cycle, 1-3 cycles) is used or not concurrent with radiotherapy. There is no order of Kanglaite injection and radiotherapy. Granulocyte colony stimulating factor and antibiotics have no prophylactic use, but can be used after the decline of white blood cells. Mucositis, nutritional status, and quality of life are evaluated before radiotherapy, every week of radiotherapy, 4 weeks after radiotherapy. Mucositis is verified by physical examination. Nutritional status is evaluated by patient-generated subjective global assessment (PG-SGA) scale. Quality of life is evaluated by EORTC QLQ-C30 and QLQ-H\&N35 questionnaire.

This is a one arm study, sample size calculation based on the incidence of 3-4 degree mucositis. The incidence of 3-4 degree mucositis is about \>50% according to literatures of head and neck squamous cell carcinoma intensity modulated radiation therapy concurrent with chemotherapy. So we assume that Kanglaite can reduce 3-4 degree mucositis from 50% to 30%. The sample size required 44 cases according to the superiority test, bilateral Class I error α = 0.05, class II error β = 0.2. Total 49 cases are need, assuming the off rate of 10%.
INTRODUCTION: Lower respiratory tract infections (LRTIs) are a common cause of morbidity and mortality worldwide. Accurate identification of the pathogens causing LRTIs is crucial for ensuring of diagnostic and antibiotic stewardship. The Biofire Pneumonia Panel (BFPP) is a molecular diagnostic test that allows rapid detection of various bacterial and viral pathogens. In this study, we compared the performance of BFPP with standard culture methods for the detection of pathogens.
MATERIALS AND METHODS: Respiratory samples from 70 patient with suspected LRTIs were tested using both BFPP and standard culture methods. The distribution of isolated bacterial pathogens was analyzed, and the sensitivity and specificity of BFPP were calculated. Additionally, the performance of BFPP in detecting antimicrobial resistance genes was evaluated. The results were compared with those obtained from VITEK-2 antimicrobial susceptibility testing and culture-based methods.
RESULTS: Among the suspected LRTI cases, BFPP identified a single pathogen in 32.8% of cases and multiple pathogens in 40% of cases. The standard culture method detected a single pathogen in 47.1% of cases. BFPP showed a sensitivity of 93.9% and a specificity of 45.9% for the total sample. The performance of BFPP in detecting antimicrobial resistance genes varied for different pathogens with overall sensitivity of 40.1% and specificity of 95.9%.
CONCLUSION: The Biofire Pneumonia Panel (BFPP) demonstrated high sensitivity for several bacterial pathogens, indicating its potential as a rapid diagnostic tool. However, its performance varied for different microorganisms, and it had limitations in detecting certain pathogens and antimicrobial resistance genes for which still required more further studies to explore different resistance gene mechanism that can be incorporated in this panel in future. The BFPP can complement standard culture methods as a rapid tool in the diagnosis of LRTIs.
<P>PROBLEM TO BE SOLVED: To provide a new beauty agent raw material for preventing or retarding the appearance of skin ageing symptom, or weakening an effect thereof.  <P>SOLUTION: The invention relates to the use of a plant extract as a beauty agent. The extract is obtained as a beauty-activating agent from a plant belonging to the genus Citrus or from a hybrid obtained by the hybridization of plant species whose at least one belongs to the genus Citrus. The extract is obtained from a plant belonging the genus ×Citrofortunella. Especially, the extract of calamondin (×Citrofortunella microcarpa) is suitable. The extract can prevent or retard the appearance of skin ageing symptoms, weaken the effect thereof, and/or improve or recover the gloss or bright glow of the skin.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Immunologic tests including Nk cell were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery). The NK cell tests were carried out in our hospital. Peripheral blood mononuclear cells were evaluated using flow cytometry via fluorochrome-conjugated antibodies against a number of NK cell receptors.
The invention discloses a euphausia superba small molecule active peptide, a preparation method and application thereof. According to the invention, the defatted euphausia superba powder is used for preparing the XOD inhibitory peptide, and the obtained polypeptide has a high XOD inhibition rate. Through LC-MS/MS identification, 5 small molecular polypeptides with XOD inhibition activity are obtained from the defatted antarctic krill powder enzymatic hydrolysate by screening: LPPYSKE, EDVEGAVR, LDLPGWVK, LDDAFNHL and WDRPLVE. These 5 polypeptides all have varying degrees of XOD inhibitory activity. The euphausia superba peptide prepared by the method has good XOD inhibition capability, and can be applied to the deep processing fields of health products, medicines and the like. The invention can utilize the byproducts of aquatic product processing in a high value, and can effectively improve the resource utilization rate and the industrial economic value.
Medicaments for the restoration of conjunctive tissue contain a triphenolic derivative. The triphenolic deriv. is usually extracted from a plant. It may, e.g. be a tannin or a tannoid. In an example, a soln. for percutaneous treatment contained 6g liquid extract of Agrimonia eupatoria, 1 ml 50% aqueous propylene glycol, and 0.05 ml sodium dioctyl sulphosuccinate aq. alcoholic soln. Eliminates marks and discoloration on the skin due to scars and stretching, and also restores arterial and vacular elasticity in cases of arteriosclerosis.
The present invention disclosed a novel Antineoplastic drug which is mainly composed of the following Chinese medicinal herbs: Panax ginsing, Poria cocos, Atractylodes macrocephala, Angelic sinensis, Astragalus membranaceus, Curcuma zedoaria, Scutellaria baicalensis, Coptis chinensis, Glycyrrhiza uralensis, Crataegus pinatifida, Hordeum vulgare, Schisandra chinensis, Hedyotis diffusa, Ophiophogon japonicus, and Lobelia chinesis lour. It has been used clinically for 20 years, including 15 years in China and 5 years in Israel. Thousands of tumor patients have taken the antineoplastic drug with 69.7 % of effective rate and 84.3 % in association with radiotherapy and chemotherapy. Clinical and experimental evidence show that it can improve the immunity of organism, inhibit and reverse tumor cells; repose, improve the circulation of blood to inhibit the growth and metastasis of tumor; increase the sensitivity to radiotherapy and chemotherapy and alleviate the toxic and side effect which resulted from them, improve somnus, enhance the appetite, alleviate pain, and protect the function of liver, kidney and ovary; and increase the number of leukocyte and hemoglobin which are reduced by radiotherapy and chemotherapy. It can also enhance the antineoplastic ability of organism, prevent the recurrence of tumor, improve the tumor patient's quality of life and prevent tumorigenesis. The animal tests performed in the University of Telaviv of Israel prove that it can increase the action capacity of NK cells, reduce and prevent the tumor metastasis under stress.
Ozone injection will be performed on patients and upper trapezius muscle stretching exercises will be given. 8 cc of oxygen/ozone gas at a concentration of 15 µg/mL will be injected into the trigger point.
A high temperature-stable and highly purified cross-linked (optionally > 70% β-β linked) tetrameric hemoglobin with high efficiency of oxygen delivery suitable for use in mammals without causing renal injury and vasoconstriction is provided. The dimeric form of hemoglobin is degenerated and purification processes are performed on red blood cells from whole blood. Controlled hypotonic lysis in an instant cytolysis apparatus prevents lysis of white blood cells. Nucleic acids from white blood cells and phospholipids impurities are not detected. Blocking of reactive sulfhydryl groups by a sulfhydryl reagent is performed in an oxygenated environment. Flowthrough column chromatography removes different plasma protein impurities. N-acetyl cysteine is added to the cross-linked tetrameric hemoglobin to maintain a low level of met-hemoglobin. The stabilized hemoglobin is preserved in an infusion bag with aluminum overwrap to prevent formation of inactive met-hemoglobin from oxygen intrusion. The product finds use in tissue oxygenation and cancer treatment.
FIELD: medicine. ^ SUBSTANCE: invention is related to alimentation, in particular - to a method and composition for improvement of glucose and insulin balance. Proposed is a compound that includes: a protein source, a fat source and a carbohydrate source, the protein source to the fat source ratio being approximately 1:1:1, each source accounting for 15% - 45% of the total calorie content of the compound. The fat source accounts for approximately over 2% of the total calorie content of the composition in the form of linoleic acid (18:2). According to an alternative version, the food compound for normalisation of insulin and glucose in the organism contains a protein source, a fat source and a carbohydrate source at a ratio of 1:1:1, each of these components accounting for approximately a third of the total calorie content of the compound. Additionally proposed are a diet for enhancement of sensitivity to insulin, a method to reduce resistivity to insulin, a method to reduce insulin levels in the plasma during after dinner time, a method to delay occurrence of insulin in one's blood and a method to increase fat clearance during after dinner time envisaging usage of the above food compound. ^ EFFECT: invention allows to improve glucose regulation and insulin effect. ^ 68 cl, 34 dwg, 38 tbl
Single oral dose of 1 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
INTRODUCTION: The MonarchE trial explored the use of abemaciclib, a CDK4/6 inhibitor, as an adjuvant treatment in high-risk early-stage luminal-like breast cancer. The study's inclusion criteria, especially the N2 status, may require revisiting surgical interventions, including invasive axillary lymph node dissection (ALND)-a procedure that current guidelines generally do not recommend.
METHODS: We conducted a single-centre, retrospective, observational cohort study on non-metastatic breast cancer patients managed from 2002 to 2011, at the Institut Curie. Data collection involved clinical and histological characteristics plus treatment follow-up.
RESULTS: Out of 8715 treated patients, 721 met the inclusion criteria. Overall, 12% (87) were classified as N2 ( ≥ 4 positive lymph nodes), thus eligible for abemaciclib per "node criterion." Tumour size, positive sentinel lymph nodes, and lobular histology showed a significant correlation with N2 status. Approximately 1000 ALNDs would be required to identify 120 N2 cases and prevent four recurrences.
CONCLUSION: The MonarchE trial may significantly affect surgical practices due to the need for invasive procedures to identify high-risk patients for adjuvant abemaciclib treatment. The prospect of unnecessary morbidity demands less invasive N2 status determination methods. Surgical decisions must consider patient health and potential treatment benefits.
The invention discloses a Chinese herbal medicine composition used for drug rehabilitation. The composition is prepared from following Chinese herbal medicine raw materials by weight: 30-100 parts of gynostemma pentaphylla, 30-50 parts of radix astragali, 30-60 parts of liquorice, 25-35 parts of rhizoma drynariae, 20-40 parts of plantain herb, and 20-60  parts of rhizoma smilacis glabrae. The Chinese herbal medicine composition has effects of tonifying body, and recovering physiological functions of internal organs, and is capable of supporting the health energy, building the body and curing wound, detoxifying and eliminating toxicity. The Chinese herbal medicine composition is a pure traditional Chinese medicine preparation, and is non-toxic, safe and reliable without side effects. After a drug addict takes the medicine, the drug addiction can be inhibited quickly and withdrew quickly with significant curative effects and a low relapse rate. The Chinese herbal medicine composition has good economic benefit and social benefit.
FIELD: medicine. ^ SUBSTANCE: group of inventions concerns medicine and pharmacology, namely to blood substitutes on the basis of polyhemoglobin. The blood substitute with function of oxygen transfer which basis is made of polymerised glutaric aldehyde haemoglobin received from blood of animals is offered, thus it represents a dry substance and contains not less than 90% of polymerised haemoglobin with molecular mass in a range 192000-320000Da, and methemoglobin content in a blood substitute makes not more than 5%. The pharmaceutical compositions containing the specified blood substitute, containing either polyvinylpyrolidone, or polyoxydin, or physiological saline, or solution of sodium chloride, potassium chloride and magnesium chloride and sodium fumarate are offered. The invention provides blood substitute creation, comparable by efficiency of oxygen transfer with erythrocytes of human blood. ^ EFFECT: creation of blood substitute, comparable by efficiency of oxygen transfer with erythrocytes of human blood. ^ 10 cl, 1 ex, 1 tbl
The prognosis of chronic kidney diseases (CKD) patients is strongly compromised by cardiovascular (CV) complications. Inflammation is established as a major risk factor for CV complications in these patients, occurring in approximately one third of them. Recently, growing evidences have suggested the body water volume expansion is a cause of inflammation in CKD. In a previous study Rodrigues Telini showed that dietary sodium restriction reduced the inflammatory markers levels in hemodialysis (HD) patients. Similar results were observed in patients treated by reduction of HD dialysate sodium concentration. However in both studies no significant reduction in body volume markers was observed. These results could be due to small number of patients or low sensibility of volume markers; on the other hand they could suggest a direct role of sodium as an inflammatory inducer independently of volume. With a larger number of patients and using a more sensitive volume marker as the B-type natriuretic peptide (BNP), this study intends to confirm the hypothesis that sodium mobilization can reduce the body water volume and attenuate the inflammatory in HD patients. A hundred thirty-five patients will be enrolled and divided in three groups with 35 patients: A, treated by reduction of 2 grams in daily sodium intake; B, exposed to reduction of sodium dialysate from 138 to 135 mEq/L and C, control group. The patients will be followed up by 16 weeks and inflammatory markers (CRP, interleukin-6, and tumor necrosis factor) as well as volume markers (Watson formula, electrical bioimpedance measurements and BNP concentration) will be determine each 8 weeks.